Epcoritamab Plus R-CHOP Improves Survival in Lymphoma Trial

Genmab and AbbVie announced that epcoritamab, used in combination with the standard chemotherapy regimen R-CHOP, demonstrated a statistically significant improvement in progression-free survival among patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL), according to results from a clinical trial.

DLBCL is the most common form of aggressive non-Hodgkin lymphoma, and R-CHOP has long served as the backbone of first-line treatment. The announcement signals that adding epcoritamab — a bispecific antibody developed jointly by Genmab and AbbVie — to this established regimen may raise the bar for front-line care in a disease where a significant share of patients still experience relapse.

Read more Korro Bio Doses First Patients in Phase 1/2 Trial for KRRO-121 →

The trial result is notable because progression-free survival was the primary endpoint, meaning the study was specifically designed and powered to detect a meaningful difference in how long patients lived without their disease worsening. Achieving statistical significance on that measure represents a key regulatory and clinical milestone for the drug combination.

The finding positions epcoritamab as a potential new standard-of-care option for newly diagnosed DLBCL, a patient population that has seen limited therapeutic advances in recent years despite broad research investment. Analysts will likely watch for the companies to pursue regulatory submissions based on the data, though no timeline for filings was specified in the announcement.

Continue reading at GlobeNewswire - Industry News on Financial Services.